Elena Durán González

Dr. Elena Durán González

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2024 in International Journal of Rheumatic Diseases
Verified
Journal Article
Open access
JPJuan Francisco Palma‐Ordóñez
Juan Francisco Palma‐Ordóñez
AMAna María Moreno‐Fernández
Ana María Moreno‐Fernández
Jorge Antolín Ramírez TejeroJorge Antolín Ramírez Tejero
Jorge Antolín Ramírez Tejero
EGElena Durán González
Elena Durán González
AMAntonio Martínez‐Lara
Antonio Martínez‐Lara
DCDavid Cotán
David Cotán
Fibromyalgia (FM) is a highly prevalent chronic disease. About 4.7% of the world's population suffers from generalized pain and hypersensitivity, in addition to a wide range of physical and psychological symptoms. The etiopathogenesis of this disease is multifactorial, which makes its diagnosis and treatment challenging. Recently, the increase in the number of studies on microbiota has provided new data that can help to understand the onset and development of FM. An updated systematic review of the causes of FM has been carried out in this work. Particularly in the last decade, research has focused on the gut–brain axis, which has emerged as a crucial mechanism for microbiota‐host crosstalk. In FM patients, quantitative imbalances of the intestinal microbiota (dysbiosis) and bacterial metabolites with differential relative abundance have been found, especially short‐chain fatty acids and lipopolysaccharides. Furthermore, the microbiota has been found to indirectly influence host neurotransmitter mechanisms, mainly through the serotonin precursor, glutamate, and gamma‐aminobutyric acid. Thus, all these mechanisms and their influence on the etiopathogenesis of FM are discussed in this review.

12 July 2023 in Neurology International
Verified
Journal Article
Open access
PDF file
Jorge Antolín Ramírez TejeroJorge Antolín Ramírez Tejero
Jorge Antolín Ramírez Tejero
EGElena Durán González
Elena Durán González
AMAntonio Martínez-Lara
Antonio Martínez-Lara
LALaura Lucena del Amo
Laura Lucena del Amo
ISIsabel Sepúlveda
Isabel Sepúlveda
DCDavid Cotán
David Cotán
Fibromyalgia is a widespread chronic condition characterized by pain and fatigue. Among the long list of physiological disturbances linked to this syndrome, mitochondrial imbalance and oxidative stress stand out. Recently, the crosstalk between mitochondria and intestinal microbiota has caught the attention of biomedical researchers, who have found connections between this axis and several inflammatory and pain-related conditions. Hence, this pilot descriptive study focused on characterizing the mitochondrial mass/mitophagy ratio and total antioxidant capacity in PBMCs, as well as some microbiota components in feces, from a Peruvian cohort of 19 females and 7 males with FM. Through Western blotting, electrochemical oxidation, ELISA, and real-time qPCR, we determined VDAC1 and MAP1LC3B protein levels; total antioxidant capacity; secretory immunoglobulin A (sIgA) levels; and Firmicutes/Bacteroidetes, Bacteroides/Prevotella, and Roseburia/Eubacterium ratios; as well as Ruminococcus spp., Pseudomonas spp., and Akkermansia muciniphila levels, respectively. We found statistically significant differences in Ruminococcus spp. and Pseudomonas spp. levels between females and males, as well as a marked polarization in mitochondrial mass in both groups. Taken together, our results point to a mitochondrial imbalance in FM patients, as well as a sex-dependent difference in intestinal microbiota composition.

2 October 2025 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
EGElena Durán González
Elena Durán González
JRJorge Antolín Ramírez-Tejero
Jorge Antolín Ramírez-Tejero
MPMarta Pérez-Sánchez
Marta Pérez-Sánchez
CMCarmen Morales-Torres
Carmen Morales-Torres
RGRosa Gómez-Morano
Rosa Gómez-Morano
DCDavid Cotán
David Cotán
Background: Fibromyalgia is a complex disorder whose main symptoms are chronic widespread pain and fatigue and affects between 0.2 and 6.6% of the world population. Nowadays, there are no molecular biomarkers that could facilitate diagnosis. The latest efforts by researchers have focused on studying problems at the level of central nervous system sensitivity, inflammation, and oxidative disorders.Methods: A total of 892 women were initially enrolled in the study. For individuals who met the inclusion criteria, a plasma proteome analysis was conducted using blood samples. Briefly, blood was collected, centrifuged, and analyzed by liquid nano-chromatography coupled to tandem mass spectrometry. After the raw data analysis, proteins with statistically significant differential abundance and a fold change over 1.2 (20% increase in fibromyalgia compared with control samples) or under 0.8 (20% decrease in fibromyalgia compared with control samples) in fibromyalgia were selected. For fecal metagenome analysis, fecal samples were collected and processed for DNA extraction. Amplicon sequencing of V3–V4 regions from the 16S ribosomal RNA gene was performed using the Illumina MiSeq platform. The statistical analysis was conducted using R v4.3.2 base packages.Results: After applying exclusion criteria, 242 women (199 patients and 43 age- and environmentally paired controls) provided plasma and feces samples, as well as properly filled health questionnaires. A total of 30 proteins and 19 taxa were differentially expressed in fibromyalgia patients, and their integration into an algorithm allows for discrimination between cases and controls. The multi-omic approach for biomarker discovery in this study proposes a multifactorial connection between gut microbiota and mitochondria-derived oxidative stress and inflammation.Conclusions: Plasma and fecal multi-omics analysis suggest an intricate and multifactorial connection between gut microbiota and mitochondria-derived oxidative stress and inflammation in FM patients, with glyceraldehyde-3-phosphate dehydrogenase and Streptococcus salivarius as leading actors.Trial registration: NCT05921409.

26 May 2026 in Life
Verified
Journal Article
Open access
PDF file
EGElena Durán González
Elena Durán González
Jorge Antolín Ramírez TejeroJorge Antolín Ramírez Tejero
Jorge Antolín Ramírez Tejero
IMIsmael San Mauro Martin
Ismael San Mauro Martin
ALAna Terrén Lora
Ana Terrén Lora
MSMarta Pérez Sánchez
Marta Pérez Sánchez
DCDavid Cotán
David Cotán
Fibromyalgia is a chronic syndrome associated with pain, fatigue, and cognitive symptoms, often linked to gut microbiota alterations. The Mediterranean Diet (MD), particularly extra-virgin olive oil (EVOO), has antioxidant and anti-inflammatory properties that may beneficially modulate the microbiota. We conducted a prospective, randomized, double-blind, placebo-controlled clinical trial that included 250 women (206 with fibromyalgia, 44 controls). Participants followed a MD supplemented with EVOO or refined olive oil (placebo) for six months. Microbiota composition was analyzed at four time points (T0–T3) by 16S rRNA sequencing (V3–V4). At baseline, fibromyalgia patients exhibited reduced microbial diversity compared to controls. While global diversity did not change after intervention, specific taxa increased significantly with EVOO, including Bacteroides fragilis, Anaerotruncus colihominis, Adlercreutzia equolifaciens, and butyrate producers such as Faecalibacterium prausnitzii, Roseburia intestinalis, and Agathobacter. These shifts suggest EVOO supplementation might promote anti-inflammatory and metabolic bacteria, suggesting diet as a complementary strategy to modulate gut microbiota in fibromyalgia.